Bli medlem
Bli medlem

Du är här


Novartis International AG: Novartis Wins Two Prestigious Prix Galien Foundation Awards; Gleevec® recognized as "Discovery of the Decade" for Best Pharmaceutica

Novartis International AG / Novartis Wins Two Prestigious Prix Galien
Foundation Awards; Gleevec® recognizedas "Discovery of the Decade" for Best
Pharmaceutical Product, Cosentyx® as Best Biotechnology Product. Processed
and transmitted by Nasdaq Corporate Solutions. The issuer is solely
responsible for the content of this announcement.
Basel, October 31, 2016
Novartis has been awarded the prestigious 2016 Prix Galien USA Award for Best
Biotechnology Product for Cosentyx® (secukinumab), as well as the Prix Galien
Foundation "Discovery of the Decade" Award for Best Pharmaceutical Product
for the drug Gleevec® (imatinib mesylate). The awards were presented at a
ceremony in New York City.

"We are honored to receive these prestigious awards for Cosentyx and Gleevec,
which not only have changed the practice of medicine for certain conditions,
but also represent years of hard work by our scientists," said Joseph
Jimenez, CEO of Novartis. "These wins underscore our commitment to addressing
the unmet medical needs of patients through science-based innovation."

Cosentyx was the first fully human interleukin-17A (IL-17A) antagonist
approved by the US Food and Drug Administration (FDA) in 2015 for the
treatment of adults with moderate to severe plaque psoriasis[1]. Psoriasis
affects an estimated 7.5 million people in the US[2]. It is a chronic
immune-mediated disease characterized by thick and extensive skin lesions
(plaques), which can cause itching, scaling, and pain[2]. Cosentyx was also
approved for the treatment of active ankylosing spondylitis and psoriatic
arthritis in 2016[1].

The discovery of Gleevec marked the first time in the history of cancer
treatment that scientists were able to identify a chromosomal abnormality and
then develop a drug that would target that specific protein. Gleevec, a
molecularly targeted treatment, rapidly became a therapy of choice for
Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) and KIT
(CD117)-positive gastrointestinal stromal tumors (KIT+ GIST)[3]. By showing
that certain diseases can share a drug-sensitive target with seemingly
unrelated ailments, and that molecular targeting can be medically and
commercially successful, Gleevec helped establish a new paradigm for drug

About the Prix Galien Awards

Considered "the pharmaceutical industry's Nobel Prize," the Prix Galien
rewards excellence in scientific innovation that improves the state of human
health. The award was first established in 1970 by French pharmacist Roland
Mehl and was inaugurated in the United States in 2007 to recognize the
technical, scientific and clinical research skills necessary to develop
innovative medicines. Since 1970, Novartis has received more than 40 national
Prix Galien awards in fifteen countries for innovative therapies such as
Gleevec® (imatinib mesylate), Rimactane® (rifampin), Parlodel® (bromocriptine
mesylate), Sandimmune® (cyclosporine), Sandostatin® (octreotide acetate),
Simulect® (basiliximab) and Visudyne® (verteporfin)[4].

The "Discovery of the Decade" is a special once-in-10-years recognition for
distinguished industry achievement in medical innovation. The awards honor
extraordinary human health impact in three categories - Best Pharmaceutical
Product, Best Biotechnology Product, and Best Medical Technology. In addition
to Gleevec® (imatinib mesylate), two other Novartis products were nominated
for "Discovery of the Decade," including Coartem® (artemether/ lumefantrine)
for Best Pharmaceutical Product and Promacta® (eltrombopag olamine) for Best
Biotechnology Product. Gleevec won the Prix Galien International Prize in
2002, and was recognized again in 2009 by the Prix Galien USA committee for
"Best Pharmaceutical Product"[5].

About Cosentyx and interleukin-17A (IL-17A)

Cosentyx is a fully human monoclonal antibody (mAB) that selectively binds to
the interleukin-17A (IL-17A) cytokine and inhibits its interaction with the
IL-17 receptor[1].

Cosentyx is approved in more than 65 countries for the treatment of moderate
to severe plaque psoriasis which includes the European Union countries,
Japan, Switzerland, Australia, the U.S. and Canada[6]. In the U.S., Cosentyx
is approved for the treatment of moderate to severe plaque psoriasis in adult
patients who are candidates for systemic therapy or phototherapy (light
therapy). Cosentyx is also approved in the US for adult patients with active
ankylosing spondylitis and active psoriatic arthritis[1].

More than 10,000 patients have been treated with Cosentyx in clinical trial
settings across multiple indications, and over 50,000 patients have been
treated in the post-marketing setting worldwide[7].

About Gleevec (imatinib mesylate)

Gleevec® (imatinib mesylate) tablets are indicated for newly diagnosed adult
patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+
CML) in the chronic phase (CP). Gleevec is also indicated for the treatment
of patients with Ph+ CML in blast crisis (BC), accelerated phase (AP), or in
CP after failure of interferon-alpha therapy.

Additionally, Gleevec is indicated for Patients with KIT(CD117)-positive
gastrointestinal stromal tumors (GIST) that cannot be surgically removed
and/or have spread to other parts of the body and for adult patients after
surgery who have had their KIT (CD117)-positive GIST completely removed.


COSENTYX®(secukinumab) is a prescription medicine used to treat adults:

* with moderate to severe plaque psoriasis that involves large areas or many
areas of the body, and who may benefit from taking injections or pills
(systemic therapy) or phototherapy (treatment using ultraviolet or UV
light, alone or with systemic therapy)
* with active psoriatic arthritis
* with active ankylosing spondylitis


Do not use COSENTYX if you have had a severe allergic reaction to secukinumab
or any of the other ingredients in COSENTYX. See the Medication Guide for a
complete list of ingredients.

COSENTYX is a medicine that affects your immune system. COSENTYX may increase
your risk of having serious side effects such as:


COSENTYX may lower the ability of your immune system to fight infections and
may increase your risk of infections.

* Your doctor should check you for tuberculosis (TB) before starting
treatment with COSENTYX.
* If your doctor feels that you are at risk for TB, you may be treated with
medicine for TB before you begin treatment with COSENTYX and during
treatment with COSENTYX.
* Your doctor should watch you closely for signs and symptoms of TB during
treatment with COSENTYX.Do not take COSENTYX if you have an active TB

Before starting COSENTYX, tell your doctor if you:

* are being treated for an infection
* have an infection that does not go away or that keeps coming back
* have TB or have been in close contact with someone with TB
* think you have an infection or have symptoms of an infection such as:

| * fevers, sweats, or chills * warm, red, or painful skin or sores on your body |
| * muscle aches * diarrhea or stomach pain |
| * cough * burning when you urinate or urinate more often than normal |
| * shortness of breath |
| * blood in your phlegm |
| * weight loss |
After starting COSENTYX, call your doctor right away if you have any signs of
infection listed above.
Do not use COSENTYX if you have any signs of infection unless you are
instructed to by your doctor.

Inflammatory Bowel Disease

New cases of inflammatory bowel disease or "flare-ups" can happen with
COSENTYX, and can sometimes be serious. If you have inflammatory bowel
disease (ulcerative colitis or Crohn's disease), tell your doctor if you have
worsening disease symptoms during treatment with COSENTYX or develop new
symptoms of stomach pain or diarrhea.

Serious Allergic Reactions

Serious allergic reactions can occur. Get emergency medical help right away if
you get any of the following symptoms: feeling faint; swelling of your face,
eyelids, lips, mouth, tongue, or throat; trouble breathing or throat
tightness; chest tightness; or skin rash. If you have a severe allergic
reaction, do not give another injection of COSENTYX.

Before starting COSENTYX, tell your doctor if you:

* have any of the conditions or symptoms listed above for infections
* have inflammatory bowel disease (Crohn's disease or ulcerative colitis)
* are allergic to latex. The needle caps contain latex.
* have recently received or are scheduled to receive an immunization
(vaccine). People who take COSENTYXshould not receive live vaccines.
* have any other medical conditions
* are pregnant or plan to become pregnant. It is not known if COSENTYX can
harm your unborn baby. You and your doctor should decide if you will use
* are breastfeeding or plan to breastfeed. It is not known if COSENTYX passes
into your breast milk.

Tell your doctor about all the medicines you take
, including prescription and over-the-counter medicines, vitamins, and herbal
supplements. Know the medicines you take. Keep a list of your medicines to
show your doctor and pharmacist when you get a new medicine.

How should I use COSENTYX?

See the detailed Instructions for Use that comes with your COSENTYX for
information on how to prepare and inject a dose of COSENTYX, and how to
properly throw away (dispose of) used COSENTYX Sensoready® pens and prefilled

* Use COSENTYX exactly as prescribed by your doctor.
* If your doctor decides that you or a caregiver may give your injections of
COSENTYX at home, you should receive training on the right way to prepare
and inject COSENTYX. Do not try to inject COSENTYX yourself, until you or
your caregiver has been shown how to inject COSENTYX by your doctor or

The most common side effects of COSENTYX include:
cold symptoms, diarrhea, and upper respiratory infections. These are not all
of the possible side effects of COSENTYX. Call your doctor for medical advice
about side effects.
You are encouraged to report negative side effects of prescription drugs to
the FDA., or call 1-800-FDA-1088.

Please see accompanying fullPrescribing Information, includingMedication

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.